Phase IISmall Molecule
Compound 61693
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061693
Risk Class
HIGH
Last Audit
Jun 15, 2108
Research Abstract
Small Molecule candidate engineered for oncology adjuvant initiatives with automated dossier coverage.
Compound 61693 is a small molecule asset inside small molecule innovation track initiatives, optimized for oncology adjuvant and inflammation control.
The dossier currently sits in phase ii with a high risk rating, meaning it is restricted to black-box teams with hardened compliance.
Supply records cite CAS AUTO-061693 with updates logged 2108-06-15.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Oncology adjuvantInflammation control
Nomenclature
CX-61693Small Molecule Program 61693
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061693
- [2] Operations Pulse • Small Molecule innovation track
- [3] Risk Governance Ledger • HIGH clearance for COMPOUND-61693